Canada markets open in 9 hours 4 minutes
  • S&P/TSX

    20,725.00
    +96.08 (+0.47%)
     
  • S&P 500

    4,164.00
    +52.92 (+1.29%)
     
  • DOW

    34,156.69
    +265.67 (+0.78%)
     
  • CAD/USD

    0.7465
    -0.0003 (-0.04%)
     
  • CRUDE OIL

    77.35
    +0.21 (+0.27%)
     
  • BTC-CAD

    31,149.25
    +290.19 (+0.94%)
     
  • CMC Crypto 200

    536.91
    +10.96 (+2.08%)
     
  • GOLD FUTURES

    1,888.60
    +3.80 (+0.20%)
     
  • RUSSELL 2000

    1,972.61
    +14.89 (+0.76%)
     
  • 10-Yr Bond

    3.6740
    +0.0400 (+1.10%)
     
  • NASDAQ futures

    12,781.75
    +5.00 (+0.04%)
     
  • VOLATILITY

    18.66
    -0.77 (-3.96%)
     
  • FTSE

    7,864.71
    +28.00 (+0.36%)
     
  • NIKKEI 225

    27,572.13
    -113.34 (-0.41%)
     
  • CAD/EUR

    0.6954
    -0.0003 (-0.04%)
     

Is This Chinese Pharmaceutical Stock Worth the Risk?

Is This Chinese Pharmaceutical Stock Worth the Risk?

BeiGene (NASDAQ: BGNE), is a Chinese biopharmaceutical company with offices in Cambridge, Massachusetts; Basel, Switzerland; and Beijing. It focuses on unique therapies to treat cancer, specializing in B-cell malignancies and solid tumors in lung and gastrointestinal cancers. Amid delisting concerns, a lot of Chinese stocks have fallen this year.